Marinus Pharmaceuticals, Inc. (MRNS)
NASDAQ: MRNS · IEX Real-Time Price · USD
1.420
-0.040 (-2.74%)
At close: May 31, 2024, 4:00 PM
1.480
+0.060 (4.23%)
After-hours: May 31, 2024, 7:32 PM EDT
Marinus Pharmaceuticals Stock Forecast
MRNS's stock price has decreased by -80.03% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 8 analysts with 12-month price forecasts for MRNS stock have an average target of 11.75, with a low estimate of 2.00 and a high estimate of 28. The average target predicts an increase of 727.46% from the current stock price of 1.42.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for MRNS stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 5 | 5 | 5 | 4 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +674.65% | May 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $27 → $11 | Strong Buy | Maintains | $27 → $11 | +674.65% | May 7, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $25 → $10 | Strong Buy | Maintains | $25 → $10 | +604.23% | Apr 17, 2024 |
| Baird | Baird | Buy → Hold Downgrades $20 → $2 | Buy → Hold | Downgrades | $20 → $2 | +40.85% | Apr 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $27 | Strong Buy | Reiterates | $27 | +1,801.41% | Apr 16, 2024 |
Financial Forecast
Revenue This Year
40.13M
from 30.99M
Increased by 29.50%
Revenue Next Year
59.33M
from 40.13M
Increased by 47.84%
EPS This Year
-2.00
from -2.63
EPS Next Year
-1.06
from -2.00
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 56.1M | 94.4M | 167.0M | 517.6M | 887.9M |
| Avg | 40.1M | 59.3M | 121.1M | 228.0M | 352.0M |
| Low | 33.3M | 36.7M | 58.9M | 103.1M | 191.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 80.9% | 135.2% | 181.4% | 327.4% | 289.4% |
| Avg | 29.5% | 47.8% | 104.1% | 88.3% | 54.4% |
| Low | 7.6% | -8.7% | -0.8% | -14.9% | -16.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.51 | -0.62 | -0.11 | 0.18 | 0.46 |
| Avg | -2.00 | -1.06 | -0.36 | 0.17 | 0.45 |
| Low | -2.53 | -2.02 | -0.62 | 0.17 | 0.43 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 166.4% |
| Avg | - | - | - | - | 158.8% |
| Low | - | - | - | - | 148.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.